A 3-day Course for CFS/ME
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNorwegian University of Science and Technology
About this trial
Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal problem.
In recent years, a doubling of the number of patients with a CFS/ME diagnoses has been reported in Norway. The patient group represents a challenge for the health care system, the municipality, and the Norwegian Labour and Welfare Organization (NAV). According to new figures, the NAV pays 100 million Norwegian Kroner (NOK) each month in permanently incapacitated expenses for people with CFS/ME. Municipalities have expenses in form of care, rehabilitation and other measures.
There is a lack of effective treatment for CFS/ME. Evidence-based knowledge is highly needed.
If the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.
Eligibility criteria
Qualifiers
CFS/ME diagnosis based on the Canada Consensus Criteria.
At least 50% out of school/work.
Readiness to change (corresponding to the preparation phase in transtheoretical model)
Has given informed consent.
Disqualifiers
Underlying physical illness or mental disorder that may explain the symptoms.
Suicide risk/previous suicide attempts.
Pregnancy.
Bedridden and in need of continuous care.
Trial design
Treatments tested in this trial
- A 3-day course
- Waiting list
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Norwegian University of Science and Technology
Lead sponsor
University of Oslo
Collaborator
Haukeland University Hospital
Collaborator
Lørenskog municipality
Collaborator
The Research Council of Norway
Collaborator
Source ClinicalTrials.gov